US2012225818A1PendingUtilityA1

Plasma protein effective for suppressing cough

Assignee: KAMEI SHINTAROPriority: Aug 6, 2009Filed: Aug 5, 2010Published: Sep 6, 2012
Est. expiryAug 6, 2029(~3.1 yrs left)· nominal 20-yr term from priority
A61K 38/17A61P 11/14C12N 9/6443A61P 11/00A61K 38/18A61K 38/03A61K 38/36A61K 38/4846
40
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier,
 wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.   
     
     
         2 . The pharmaceutical composition according to  claim 1 , wherein the cough is caused by stimulation at the tracheal bifurcation. 
     
     
         3 . A method of prevention, treatment and/or symptom amelioration of cough in a mammal, comprising administering to the mammal an effective amount of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences. 
     
     
         4 . The method according to  claim 3 , wherein the cough is caused by stimulation at the tracheal bifurcation.

Join the waitlist — get patent alerts

Track US2012225818A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.